Effects of Initiating Carvedilol in Patients with Severe Chronic Heart Failure: Results from the COPERNICUS Study

JAMA

Volumn 289, Issue 6, 2003, Pages 712-718

  Krum, Henry ^a   Roecker, Ellen B ^b   Mohacsi, Paul ^c   Rouleau, Jean L ^e   Tendera, Michal ^d   Coats, Andrew J S ^f   Katus, Hugo A ^g   Fowler, Michael B ^h   Packer, Milton ⁱ  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; METOPROLOL; PLACEBO; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VERTIGO; CONGESTIVE HEART FAILURE; MULTICENTER STUDY; RISK; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DOUBLE-BLIND METHOD; HEART FAILURE, CONGESTIVE; HUMANS; PROPANOLAMINES; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037433183     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.6.712     Document Type: Article

References (28)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
2. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomised trial. Lancet. 1999;353:9-13.
3. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Study Group. Effect of metoprolol CR/XL in chronic heart failure. Lancet. 1999;353:2001-2007.
4. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295-1302.
5. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation. 1996;94:2793-2799.
6. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800-2806.
7. Krum H, Tonkin AM, Currie R, Djundjek R, Johnston CI. Chronic heart failure in Australian general practice: The Cardiac Awareness Survey and Evaluation (CASE) study. Med J Aust. 2001;174:439-444.
8. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997;79:794-798.
9. Waagstein F, Caidahl K, Wallentin I, Bergh C, Hjalmarson A. Long term a-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551-563.
10. Epstein SE, Braunwald E. The effect of beta-adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med. 1966;75:20-27.
11. Packer M, Cohn JN, eds. Consensus recommendations for the treatment of chronic heart failure. Am J Cardiol. 1999;83(suppl 2A):1A-38A.
12. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation. 2000;101:378-384.
13. Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? [abstract]. Circulation. 1995;92(suppl I):I-395.
14. Anderson JL, Krause-Steinrauf H, Goldman S, et al. Failure of benefit and early hazard of bucindolol in class IV heart failure [abstract]. Circulation. 2000;102(suppl II):II779-II780.
15. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
16. Gottlieb SS, Fischer ML, Kjekshus J, et al. MERIT-HF: tolerability of β-blocker initiation NYHA II, III, and IV CHF [abstract]. Circulation. 2000;102(suppl II):II778.
17. Gottlieb SS, Fischer ML, Kjekshus J, et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation. 2002;105:1182-1188.
18. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
19. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;34:187-202.
22. Lechat P, Bouzamondo A, Sanchez P, Hulot JS, Eichhorn EJ, Cucherat M. Relationships between baseline risk and treatment effect of beta-blockers in heart failure [abstract]. Eur Heart J. 2000;21:297A.
23. Cohn JN, Levine B, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
24. Gaffney TE, Braunwald E. Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 1963;34:320-324.
25. Australia-New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet. 1997;349:375-380.
26. Bristow M, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
27. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med. 2001;110(suppl 7A):81S-94S.
28. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Circulation. 2001;104:2996-3007.